SkyCell

SkyCell, founded in 2012 in Switzerland, specializes in manufacturing temperature-controlled containers for pharmaceutical supply chains. The company's hybrid containers utilize proprietary cold chain technology to monitor and optimize functions such as cooling, humidity protection, and shock absorption. These containers maintain internal temperatures ranging from -80°C to 25°C, depending on the model, and feature a patented insulation system that reflects heat radiation, enabling self-charging in cold environments. SkyCell's containers protect more than USD 2.5 billion worth of pharmaceutical goods, including vaccines, cancer treatments, and diabetes medication. The company's solution combines hardware with logistics software, leveraging simulation and operational data to provide real-time, end-to-end oversight of shipments and risk assessments throughout the supply chain. SkyCell claims its technology reduces CO2 emissions by up to 50% compared to traditional methods. The company's sustainable technologies have reportedly reduced the failure rate during transit to less than 0.05%, significantly lower than the industry standard of 4-12%. In February 2021, SkyCell expanded its product portfolio with a new frozen container for -20°C transport, completing its range of temperature-controlled solutions.